Sanofi's drug riliprubart granted orphan drug status in Japan for rare nerve disorder

From Nasdaq: 2025-06-30 01:22:00

The Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy. Current therapies for CIDP leave many patients with residual symptoms, with approximately 30% not responding to standard treatment. The drug has also received similar designations in the US and Europe, showing global recognition of its potential to address unmet needs in treating this rare neurological condition. Visit rttnews.com for more health news. (Source: RTTNews)



Read more at Nasdaq: Sanofi’s Riliprubart Receives Orphan Drug Status In Japan For Rare Nerve Disorder